Figuring out the best user experience can be a tricky process for any platform. But its particularly important in digital therapeutics, which some view as a disruptor to traditional pharmaceuticals.

Katie Jennings is a senior writer covering healthcare and AI. Pear’s stock closed at 39 cents a share on Friday, down 34% from 59 cents at yesterday’s close. The Boston-based company had raised $250 ...